Praxis Precision Medicines Inc
NASDAQ:PRAX

Watchlist Manager
Praxis Precision Medicines Inc Logo
Praxis Precision Medicines Inc
NASDAQ:PRAX
Watchlist
Price: 306.35 USD 4.19% Market Closed
Market Cap: $7.7B

Operating Margin

-3 927.5%
Current
Improving
by 3 936.8%
vs 3-y average of -7 864.4%

Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.

Operating Margin
-3 927.5%
=
Operating Income
$-293.1m
/
Revenue
$7.5m

Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.

Operating Margin
-3 927.5%
=
Operating Income
$-293.1m
/
Revenue
$7.5m

Peer Comparison

Country Company Market Cap Operating
Margin
US
Praxis Precision Medicines Inc
NASDAQ:PRAX
7.7B USD
Loading...
FR
Pharnext SCA
OTC:PNEXF
6T USD
Loading...
US
Abbvie Inc
NYSE:ABBV
394.7B USD
Loading...
US
Amgen Inc
NASDAQ:AMGN
187.9B USD
Loading...
US
Gilead Sciences Inc
NASDAQ:GILD
175B USD
Loading...
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
120.2B USD
Loading...
US
Epizyme Inc
F:EPE
94.1B EUR
Loading...
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
80.6B USD
Loading...
AU
CSL Ltd
ASX:CSL
87.4B AUD
Loading...
NL
argenx SE
XBRU:ARGX
44.1B EUR
Loading...
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
47.5B USD
Loading...

Market Distribution

Lower than 95% of companies in the United States of America
Percentile
5th
Based on 14 112 companies
5th percentile
-3 927.5%
Low
-4 087 900% — -5.1%
Typical Range
-5.1% — 14.8%
High
14.8% — 1 032 600%
Distribution Statistics
the United States of America
Min -4 087 900%
30th Percentile -5.1%
Median 6%
70th Percentile 14.8%
Max 1 032 600%

Praxis Precision Medicines Inc
Glance View

Market Cap
7.7B USD
Industry
Biotechnology

In the realm of biotechnology, Praxis Precision Medicines Inc. has emerged as a distinctive player, navigating the intricate path of neuropsychiatric and neurological disorder treatment. Founded with a mission to develop therapies that directly address the underlying causes of brain disorders, Praxis capitalizes on the integration of genetic insights and brain circuitry. This approach fuels the company’s innovative pipeline, which aims to launch first-in-class or best-in-class treatments for conditions often considered unmanageable or neglected. By leveraging deep genetic knowledge and pioneering circuit-based methodologies, Praxis concentrates its research on specific neural pathways in the hope of crafting target-specific drugs, thereby enhancing both efficacy and safety for patients. Praxis Precision Medicines generates revenue primarily through the clinical development and eventual commercialization of its drug candidates. The company invests heavily in research and development, often funded by strategic partnerships, private investments, and public offerings. As Praxis advances its drug candidates through various phases of clinical trials, it also seeks to strike beneficial collaborations with larger pharmaceutical entities, thus securing upfront payments, milestone fees, and royalties. This business model allows Praxis to sustain its scientific endeavors while setting the stage for potential revenue streams, contingent upon the successful approval and market introduction of its innovative therapies. Through this cycle of rigorous R&D and strategic partnerships, Praxis aims to transform its cutting-edge research into tangible medical solutions, contributing to its growth and financial health.

PRAX Intrinsic Value
HIDDEN
Show
What is Operating Margin?
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
How is Operating Margin calculated?

Operating Margin is calculated by dividing the Operating Income by the Revenue.

Operating Margin
-3 927.5%
=
Operating Income
$-293.1m
/
Revenue
$7.5m
What is Praxis Precision Medicines Inc's current Operating Margin?

The current Operating Margin for Praxis Precision Medicines Inc is -3 927.5%, which is above its 3-year median of -7 864.4%.

How has Operating Margin changed over time?

Over the last 3 years, Praxis Precision Medicines Inc’s Operating Margin has increased from -26 973.4% to -3 927.5%. During this period, it reached a low of -26 973.4% on Mar 31, 2023 and a high of -2 340.3% on Dec 31, 2024.

Back to Top